SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging
University of Missouri-Columbia
Summary
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Description
The investigators will employ a double-blinded randomized placebo control trial to determine the effects of 12 weeks of sodium glucose co-transporter 2 (SGLT2) inhibition with empagliflozin (10 mg daily), or matching placebo. Empagliflozin has been shown to decrease cardiovascular events and arterial stiffness in different populations. Placebo will be included for comparison purposes as empagliflozin is not a standard therapy for aging-associated arterial stiffness.
Eligibility
- Age range
- 60–80 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Able to provide consent * 60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses) * Stable anti-hypertensive medication regimen (if in use) for at least 90 days * Evidence of arterial stiffening (defined as carotid-femoral PWV \>/= 8 m/s) at the time of screening visit. Exclusion Criteria: * Diabetes * BMI\>/= 45kg/m2 * Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke * Estimated glomerular filtration rate GFR \< 29 mL/min * Active cancer (excludi…
Interventions
- DrugEmpagliflozin 10 MG
10mg Empagliflozin daily for 12 weeks
- DrugPlacebo
10mg Placebo daily for 12 weeks
Location
- University of MissouriColumbia, Missouri